PPT-Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet

Presenter MengJiun Chiou 5Sep2017 1 Introduction Lifelong antiplatelet treatment is recommended after ischaemic vascular events on the basis of trials done mainly in patients younger than 75 years . Antiplatelet Guidelines. MANAGEMENT OF ANTIPLATELET THERAPY IN ASSOCIATION WITH MINOR BLEEDING. Working Group: . James D. Douketis MD, FRCP(C); A. Graham . Turpie. MD, FRCP(C). Objectives. Interpret the Canadian Cardiovascular Society . Diana Oelofse . Descriptions of “bleeders” date back a few centuries.. The first modern description of . haemophilia. , as an example of a bleeding disorder likely came from the American physician John Otto in 1803.. Tx. : . Real-World Practice. In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx. 1. Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Presented by. Flywheel is a for-profit data and algorithm management . platform . The . mission is to support reusable and efficient long-term data . management. Over the course of one year of commercial activity we have learned that the ideals of long-term reproducibility . Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Applications. Lectures . 14-15: . CNN. . and . RNN Details. Zhu Han. University of Houston. Thanks . Xusheng. Du and Kevin Tsai For Slide Preparation. 1. CNN outline. The convolution operation. Motivation. Sent via email to markt-consultation-long-term-financingeceuropaeu 2 WICI would like to take this opportunity to respectfully submit its comments on the European Commissions Green Paper on Long Term F John H. Alexander, MD, MHS. on behalf of the PACIFIC-AMI Steering Committee and Investigators. Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction. n. ges in Clinical . T. rials for CIPN. Michael P. McDermott, Ph.D.. University of Rochester Medical Center. Measurement of outcome. Strategies for statistical analysis. Defining the study population. Adult Spinal Deformity . Surgery Outweighs the Risk of Transient Perioperative Complications. Tyler Williamson, OMS-IV, University of the Incarnate Word SOM. Peter . Passias. , MD, NYU Department of .